DePalma RG - Search Results

1

Reduction of iron stores and clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-smokers.

DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. DePalma RG, et al. Vascular. 2013 Aug;21(4):233-41. doi: 10.1177/1708538113478776. Vascular. 2013. PMID: 23518844

2

Cytokine signatures in atherosclerotic claudicants.

DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. DePalma RG, et al. J Surg Res. 2003 May 15;111(2):215-21. doi: 10.1016/s0022-4804(03)00075-1. J Surg Res. 2003. PMID: 12850465 Clinical Trial.

3

Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study.

DePalma RG, Hayes VW, May PE, Cafferata HT, Mohammadpour HA, Brigg LA, Chow BK, Shamayeva G, Zacharski LR. DePalma RG, et al. Vascular. 2006 Jul-Aug;14(4):193-200. doi: 10.2310/6670.2006.00039. Vascular. 2006. PMID: 17026909

4

Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.

Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Depalma RG, et al. J Vasc Surg. 2010 Jun;51(6):1498-503. doi: 10.1016/j.jvs.2009.12.068. Epub 2010 Mar 20. J Vasc Surg. 2010. PMID: 20304584 Free article. Clinical Trial.

5

Iron reduction benefits: positive results from a "negative" prospective randomized controlled trial.

Depalma RG, Zacharski LR. Depalma RG, et al. Vasc Endovascular Surg. 2012 Oct;46(7):596-7. doi: 10.1177/1538574412456304. Epub 2012 Aug 17. Vasc Endovascular Surg. 2012. PMID: 22903331 Clinical Trial. No abstract available.

6

The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Zacharski LR, DePalma RG, Shamayeva G, Chow BK. Zacharski LR, et al. Among authors: depalma rg. Am J Public Health. 2013 Apr;103(4):e105-12. doi: 10.2105/AJPH.2012.301163. Epub 2013 Feb 14. Am J Public Health. 2013. PMID: 23409890 Free PMC article. Clinical Trial.

7

Racial differences in iron measures and outcomes observed during an iron reduction trial in peripheral arterial disease.

Zacharski LR, Shamayeva G, Chow BK, DePalma RG. Zacharski LR, et al. Among authors: depalma rg. J Health Care Poor Underserved. 2015 Feb;26(1):243-59. doi: 10.1353/hpu.2015.0026. J Health Care Poor Underserved. 2015. PMID: 25702740 Clinical Trial.

8

Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes.

Zacharski LR, Shamayeva G, Chow BK, DePalma RG. Zacharski LR, et al. Among authors: depalma rg. Curr Diabetes Rev. 2017;13(4):428-436. doi: 10.2174/1573399813666170504163138. Curr Diabetes Rev. 2017. PMID: 28474556 Clinical Trial.

9

Optimal serum ferritin level range: iron status measure and inflammatory biomarker.

DePalma RG, Hayes VW, O'Leary TJ. DePalma RG, et al. Metallomics. 2021 Jun 11;13(6):mfab030. doi: 10.1093/mtomcs/mfab030. Metallomics. 2021. PMID: 34048587 Free PMC article.

10

Effect of Iron Levels on Women After Premature or Early-Onset Menopause.

Hayes VW, DePalma RG, Zacharski LR. Hayes VW, et al. Among authors: depalma rg. JAMA Cardiol. 2017 Apr 1;2(4):457-458. doi: 10.1001/jamacardio.2016.5082. JAMA Cardiol. 2017. PMID: 28052145 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters